In the case study, the authors report findings from a comparability assessment of epoetin alfa before and after a proposed manufacturing process change for which, they say, nonclinical assessment of structure-function relationships were not sensitive enough to identify clinically relevant differences resulting from differences in the drug’s glycosylation profile.
When biologic sponsors propose to make changes to manufacturing, they must perform comparability studies to confirm that there are no significant differences in structural or functional attributes of the drug that could cause clinically meaningful changes in safety or efficacy. If a change is complex, or if clinically relevant differences are possible, bridging studies are often required to confirm overall comparability. Such studies, say authors of a recent paper published in Journal of Pharmaceutical Sciences, have implications for demonstrations of biosimilarity.
In the case study, the authors report findings from a comparability assessment of epoetin alfa before and after a proposed manufacturing process change for which, they say, nonclinical assessment of structure-function relationships were not sensitive enough to identify clinically relevant differences resulting from differences in the drug’s glycosylation profile.
Epoetin alfa is manufactured using mammalian cell culture technology, and changes to manufacturing conditions can affect quality attributes. To assess possible effects, structural, functional, and nonclinical pharmacology studies were conducted to evaluate the drug prechange and postchange, as were clinical bridging studies: one was a single-dose crossover study in patients with chronic kidney disease (CKD), in which the predetermined equivalence criterion was that the geometric ratio of area under time concentration-time curve (AUC)-t for the postchange versus the prechange product should have a 90% confidence interval (CI) between 80% and 125%. The other was a phase 3, multicenter, randomized, double-blind hemoglobin and dose-equivalence trial that enrolled adult patients with CKD who were receiving hemodialysis.
The analytical comparability studies determined that the postchange product was comparable with the prechange material with the exception of minor quantitative differences in certain glycosylation structures that were not suspected to have an effect on biological function or safety of the drug. In vitro and in vivo functional assays showed the postchange product to be equivalent to the prechange product in terms of potency and pharmacodynamics.
In the single-dose crossover study, 30 patients initiated and completed the study, and the geometric ratio of AUC the from time zero to the last time sampled for the prechange and postchange product met predefined criteria for demonstrating bioequivalence (90% CI, 94.8%-104.3%).
However, in the phase 3 study in 462 patients, the log dose-ratio difference was −0.15 (90% CI, −0.25 to −0.06), demonstrating the postchange drug was more potent than the prechange drug, with the 90% CI values falling outside the prespecified equivalence margin. The researchers ultimately determined that the difference in potency was attributable to an increase in lactosamine content in the postchange epoetin alfa.
“These results illustrate that initial assumptions about the clinical relevance of certain structural attributes...may be incorrect,” write the authors. “We found in this case study that the common approach to assess the relevance of these observed structural differences using common in vitro functional assays may result in misleading conclusions and contribute to confirmation bias.”
This case study underscores the importance of the stepwise development exercise needed for biosimilar approval; the scope and burden of proof for each step in the exercise, say the authors, is informed by the residual uncertainty in the previous stages, as well as by limitations and sensitivities of any part of the clinical program to detect relevant differences.
Reference
Grampp G, McElroy PL, Camblin G, Pollock A. Structure-function relationships for recombinant erythropoietins: a case study from a proposed manufacturing change with implications for erythropoietin biosimilar study designs [Published online February 4, 2018]. J Pharm Sci. doi: 10.1016/j.xphs.2018.01.018.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.